Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M176,701Revenue (TTM) $M49,436Net Margin (%)13.5Altman Z-Score2.5
Enterprise Value $M193,097EPS (TTM) $2.8Operating Margin %16.7Piotroski F-Score5
P/E(ttm)27.1Beneish M-Score-2.7Pre-tax Margin (%)15.7Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %-2.5Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %-3.9Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow22.0y-y EBITDA Growth Rate %-0.7ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.7PEG--ROE % (ttm)9.0Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,374ROIC % (ttm)7.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NVS is held by these investors:



NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15394.6view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
    Novartis Has Bright Future Feb 01 2017 
    2 Top Health Care Dividend Stocks Jan 12 2017 
    7 Stocks With Low P/S Ratios Jan 11 2017 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
    The Pharmaceutical Sector Looks Attractive Oct 12 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novartis Is Surviving Oct 03 2016 

    More From Other Websites
    4:09 am Novartis' Alcon unit receives FDA approval for its AcrySof IQ ReSTOR +2.5 Multifocal Toric... Mar 23 2017
    Novartis' Acute Heart Failure Drug Fails in Late-Stage Study Mar 22 2017
    Novartis cancer drug combo developed partly in Cambridge shows early promise Mar 22 2017
    Novartis Heart Drug Flops In Second Late-Stage Trial — As Expected Mar 22 2017
    Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials Mar 22 2017
    Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN) Mar 22 2017
    Does Novartis (NVS) Stock Make a Good Value Pick? Mar 21 2017
    6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017 Mar 21 2017
    Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) Mar 21 2017
    Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks Mar 21 2017
    Novartis (NVS) Announces Positive Data on Heart Failure Drug Mar 20 2017
    Novartis Heart Failure Drug Beats Enalapril (NVS) Mar 20 2017
    Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition Mar 16 2017
    Novartis AG :NVS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
    Novartis Introduces Flexible Pricing for Kisqali Mar 15 2017
    Turning Pfizer Discards Into Novartis Gold: The Story Of Ziarco Mar 15 2017
    Novartis Breast Cancer Drug Just OK'd — And Already Losing? Mar 14 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)